Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review

被引:123
作者
Dagens, Andrew [1 ]
Sigfrid, Louise [1 ]
Cai, Erhui [1 ]
Lipworth, Sam [2 ]
Cheung, Vincent [3 ]
Harris, Eli [4 ]
Bannister, Peter [5 ]
Rigby, Ishmeala [5 ]
Horby, Peter [1 ]
机构
[1] Univ Oxford, Epidem Res Grp, Oxford OX3 7LG, England
[2] Univ Oxford, Modernising Med Microbiol, Oxford, England
[3] Univ Bristol, Ctr Res Synth & Decis Anal, Bristol, Avon, England
[4] Univ Oxford, Bodleian Lib, Oxford, England
[5] Brighton & Sussex Med Sch, Sch Med, Brighton, E Sussex, England
来源
BMJ-BRITISH MEDICAL JOURNAL | 2020年 / 369卷
基金
英国惠康基金;
关键词
INFECTIOUS-DISEASES; MANAGEMENT; DIAGNOSIS; SOCIETY; ADULTS;
D O I
10.1136/bmj.m1936
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
OBJECTIVE To appraise the availability, quality, and inclusivity of clinical guidelines produced in the early stage of the coronavirus disease 2019 (covid-19) pandemic. DESIGN Rapid review. DATA SOURCES Ovid Medline, Ovid Embase, Ovid Global Health, Scopus, Web of Science Core Collection, and WHO Global Index Medicus, searched from inception to 14 Mar 2020. Search strategies applied the CADTH database guidelines search filter, with no limits applied to search results. Further studies were identified through searches of grey literature using the ISARIC network. INCLUSION CRITERIA Clinical guidelines for the management of covid-19, Middle East respiratory syndrome (MERS), and severe acute respiratory syndrome (SARS) produced by international and national scientific organisations and government and non-governmental organisations relating to global health were included, with no exclusions for language. Regional/hospital guidelines were excluded. Only the earliest version of any guideline was included. QUALITY ASSESSMENT Quality was assessed using the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool. The quality and contents of early covid-19 guidelines were also compared with recent clinical guidelines for MERS and SARS. RESULTS 2836 studies were identified, of which 2794 were excluded after screening. Forty two guidelines were considered eligible for inclusion, with 18 being specific to covid-19. Overall, the clinical guidelines lacked detail and covered a narrow range of topics. Recommendations varied in relation to, for example, the use of antiviral drugs. The overall quality was poor, particularly in the domains of stakeholder involvement, applicability, and editorial independence. Links between evidence and recommendations were limited. Minimal provision was made for vulnerable groups such as pregnant women, children, and older people. CONCLUSIONS Guidelines available early in the covid-19 pandemic had methodological weaknesses and neglected vulnerable groups such as older people. A framework for development of clinical guidelines during public health emergencies is needed to ensure rigorous methods and the inclusion of vulnerable populations.
引用
收藏
页数:10
相关论文
共 41 条
[1]
[Anonymous], INT CLIN GUID MAN PA
[2]
[Anonymous], TECHN DOC CLIN MAN P
[3]
[Anonymous], NEUROLOGY S
[4]
[Anonymous], TURK COVID 19 2019 N
[5]
[Anonymous], PROT CLIN MAN NOV CO
[6]
[Anonymous], 2020, DIAGN TREATM PROT PA
[7]
[Anonymous], COREM MISSION NATL
[8]
[Anonymous], PHARM TREATMENT STRA
[9]
[Anonymous], COR DIS 19 COVID 201
[10]
[Anonymous], 2019, WHO HDB GUID DEV